{"id":87920,"date":"2019-02-18T16:03:03","date_gmt":"2019-02-19T00:03:03","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/02\/lyme-disease-vaccine-candidate-reports-study-data"},"modified":"2019-02-18T16:03:03","modified_gmt":"2019-02-19T00:03:03","slug":"lyme-disease-vaccine-candidate-reports-study-data","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/02\/lyme-disease-vaccine-candidate-reports-study-data","title":{"rendered":"Lyme Disease Vaccine Candidate Reports Study Data"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/lyme-disease-vaccine-candidate-reports-study-data.jpg\"><\/a><\/p>\n<p>Valneva SE announced final Phase 1 study data and positive initial booster data for its Lyme Disease vaccine candidate VLA15.<\/p>\n<p>\u201cThe positive final Phase 1 data for VLA15 supports and validates our plans to continue developing a safe and effective preventative vaccine that can be delivered to those who are at risk of Lyme disease infection,\u201d said Thomas Lingelbach, CEO of Valneva.<\/p>\n<p>\u201cWe look forward to continuing the development process with our recently initiated <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03769194\" target=\"_blank\">Phase 2 study<\/a>. We continue to fully commit ourselves to addressing the significant unmet need for a vaccine against Lyme disease.\u201d<\/p>\n<p><!-- Link: <a href=\"https:\/\/www.precisionvaccinations.com\/valneva%E2%80%99s-vla15-reports-positive-initial-booster-data-and-final-phase-1-study-data-its-lyme-disease\">https:\/\/www.precisionvaccinations.com\/valneva%E2%80%99s-vla1...me-disease<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Valneva SE announced final Phase 1 study data and positive initial booster data for its Lyme Disease vaccine candidate VLA15. \u201cThe positive final Phase 1 data for VLA15 supports and validates our plans to continue developing a safe and effective preventative vaccine that can be delivered to those who are at risk of Lyme disease [\u2026]<\/p>\n","protected":false},"author":513,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-87920","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/87920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/513"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=87920"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/87920\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=87920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=87920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=87920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}